Phase III randomized clinical trial comparing the effects of autologous bone marrow derived MNC and CD133 cells transplantation in ami patients during CABG

      Although the injection of Bone Marrow (BM)-derived CD133 cells in patients with recent myocardial infarction has been evaluated in our previous clinical trials, but their effects on left ventricular function in comparison with BM-derived mononuclear cells has not been yet analyzed.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect